Review



mavacamten  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress mavacamten
    <t>Mavacamten</t> (MAVA) and Omecamtiv Mecarbil (OM) drug treatments ameliorate overall nuclear stiffness in hiPSC-CMs (A) Contractility was measured through kymograph analysis: both HCM-variants I79N and R92Q showed enhanced contractile periods after 24-h treatment of 0.1 μM MAVA. The treatment also had a similar effect in the respective isogenic controls. (B) Kymograph analysis showed a decrease in contractile periods in DCM-variants R141W and R134G after 24-h treatment with 0.1 μM OM. Their respective isogenic controls demonstrated similar effects. (C) Nuclear stiffness of HCM-variants I79N and R92Q showed a significant decrease after 24-h 0.1 μM MAVA treatment. The HCM associated phenotype nuclei demonstrated values closer to their respective isogenic controls. (D) Increased nuclear stiffness was revealed in DCM-variants R141W and R134G after 24-h 0.1 μM OM treatment. One-way ANOVA was conducted to assess differences within groups; the results indicated statistically significant effects ( p < 0.0001). Data are represented as mean ± SD, with N = 10 per group.
    Mavacamten, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mavacamten/product/MedChemExpress
    Average 93 stars, based on 17 article reviews
    mavacamten - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Phenotype specific nuclear lamina remodeling in hiPSC derived cardiomyocytes bearing TNNT2 sarcomeric variants"

    Article Title: Phenotype specific nuclear lamina remodeling in hiPSC derived cardiomyocytes bearing TNNT2 sarcomeric variants

    Journal: iScience

    doi: 10.1016/j.isci.2025.113901

    Mavacamten (MAVA) and Omecamtiv Mecarbil (OM) drug treatments ameliorate overall nuclear stiffness in hiPSC-CMs (A) Contractility was measured through kymograph analysis: both HCM-variants I79N and R92Q showed enhanced contractile periods after 24-h treatment of 0.1 μM MAVA. The treatment also had a similar effect in the respective isogenic controls. (B) Kymograph analysis showed a decrease in contractile periods in DCM-variants R141W and R134G after 24-h treatment with 0.1 μM OM. Their respective isogenic controls demonstrated similar effects. (C) Nuclear stiffness of HCM-variants I79N and R92Q showed a significant decrease after 24-h 0.1 μM MAVA treatment. The HCM associated phenotype nuclei demonstrated values closer to their respective isogenic controls. (D) Increased nuclear stiffness was revealed in DCM-variants R141W and R134G after 24-h 0.1 μM OM treatment. One-way ANOVA was conducted to assess differences within groups; the results indicated statistically significant effects ( p < 0.0001). Data are represented as mean ± SD, with N = 10 per group.
    Figure Legend Snippet: Mavacamten (MAVA) and Omecamtiv Mecarbil (OM) drug treatments ameliorate overall nuclear stiffness in hiPSC-CMs (A) Contractility was measured through kymograph analysis: both HCM-variants I79N and R92Q showed enhanced contractile periods after 24-h treatment of 0.1 μM MAVA. The treatment also had a similar effect in the respective isogenic controls. (B) Kymograph analysis showed a decrease in contractile periods in DCM-variants R141W and R134G after 24-h treatment with 0.1 μM OM. Their respective isogenic controls demonstrated similar effects. (C) Nuclear stiffness of HCM-variants I79N and R92Q showed a significant decrease after 24-h 0.1 μM MAVA treatment. The HCM associated phenotype nuclei demonstrated values closer to their respective isogenic controls. (D) Increased nuclear stiffness was revealed in DCM-variants R141W and R134G after 24-h 0.1 μM OM treatment. One-way ANOVA was conducted to assess differences within groups; the results indicated statistically significant effects ( p < 0.0001). Data are represented as mean ± SD, with N = 10 per group.

    Techniques Used:



    Similar Products

    mavacamten  (MedChemExpress)
    93
    MedChemExpress mavacamten
    <t>Mavacamten</t> (MAVA) and Omecamtiv Mecarbil (OM) drug treatments ameliorate overall nuclear stiffness in hiPSC-CMs (A) Contractility was measured through kymograph analysis: both HCM-variants I79N and R92Q showed enhanced contractile periods after 24-h treatment of 0.1 μM MAVA. The treatment also had a similar effect in the respective isogenic controls. (B) Kymograph analysis showed a decrease in contractile periods in DCM-variants R141W and R134G after 24-h treatment with 0.1 μM OM. Their respective isogenic controls demonstrated similar effects. (C) Nuclear stiffness of HCM-variants I79N and R92Q showed a significant decrease after 24-h 0.1 μM MAVA treatment. The HCM associated phenotype nuclei demonstrated values closer to their respective isogenic controls. (D) Increased nuclear stiffness was revealed in DCM-variants R141W and R134G after 24-h 0.1 μM OM treatment. One-way ANOVA was conducted to assess differences within groups; the results indicated statistically significant effects ( p < 0.0001). Data are represented as mean ± SD, with N = 10 per group.
    Mavacamten, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mavacamten/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    mavacamten - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    myk 461  (TargetMol)
    94
    TargetMol myk 461
    <t>Mavacamten</t> (MAVA) and Omecamtiv Mecarbil (OM) drug treatments ameliorate overall nuclear stiffness in hiPSC-CMs (A) Contractility was measured through kymograph analysis: both HCM-variants I79N and R92Q showed enhanced contractile periods after 24-h treatment of 0.1 μM MAVA. The treatment also had a similar effect in the respective isogenic controls. (B) Kymograph analysis showed a decrease in contractile periods in DCM-variants R141W and R134G after 24-h treatment with 0.1 μM OM. Their respective isogenic controls demonstrated similar effects. (C) Nuclear stiffness of HCM-variants I79N and R92Q showed a significant decrease after 24-h 0.1 μM MAVA treatment. The HCM associated phenotype nuclei demonstrated values closer to their respective isogenic controls. (D) Increased nuclear stiffness was revealed in DCM-variants R141W and R134G after 24-h 0.1 μM OM treatment. One-way ANOVA was conducted to assess differences within groups; the results indicated statistically significant effects ( p < 0.0001). Data are represented as mean ± SD, with N = 10 per group.
    Myk 461, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/myk 461/product/TargetMol
    Average 94 stars, based on 1 article reviews
    myk 461 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Mavacamten (MAVA) and Omecamtiv Mecarbil (OM) drug treatments ameliorate overall nuclear stiffness in hiPSC-CMs (A) Contractility was measured through kymograph analysis: both HCM-variants I79N and R92Q showed enhanced contractile periods after 24-h treatment of 0.1 μM MAVA. The treatment also had a similar effect in the respective isogenic controls. (B) Kymograph analysis showed a decrease in contractile periods in DCM-variants R141W and R134G after 24-h treatment with 0.1 μM OM. Their respective isogenic controls demonstrated similar effects. (C) Nuclear stiffness of HCM-variants I79N and R92Q showed a significant decrease after 24-h 0.1 μM MAVA treatment. The HCM associated phenotype nuclei demonstrated values closer to their respective isogenic controls. (D) Increased nuclear stiffness was revealed in DCM-variants R141W and R134G after 24-h 0.1 μM OM treatment. One-way ANOVA was conducted to assess differences within groups; the results indicated statistically significant effects ( p < 0.0001). Data are represented as mean ± SD, with N = 10 per group.

    Journal: iScience

    Article Title: Phenotype specific nuclear lamina remodeling in hiPSC derived cardiomyocytes bearing TNNT2 sarcomeric variants

    doi: 10.1016/j.isci.2025.113901

    Figure Lengend Snippet: Mavacamten (MAVA) and Omecamtiv Mecarbil (OM) drug treatments ameliorate overall nuclear stiffness in hiPSC-CMs (A) Contractility was measured through kymograph analysis: both HCM-variants I79N and R92Q showed enhanced contractile periods after 24-h treatment of 0.1 μM MAVA. The treatment also had a similar effect in the respective isogenic controls. (B) Kymograph analysis showed a decrease in contractile periods in DCM-variants R141W and R134G after 24-h treatment with 0.1 μM OM. Their respective isogenic controls demonstrated similar effects. (C) Nuclear stiffness of HCM-variants I79N and R92Q showed a significant decrease after 24-h 0.1 μM MAVA treatment. The HCM associated phenotype nuclei demonstrated values closer to their respective isogenic controls. (D) Increased nuclear stiffness was revealed in DCM-variants R141W and R134G after 24-h 0.1 μM OM treatment. One-way ANOVA was conducted to assess differences within groups; the results indicated statistically significant effects ( p < 0.0001). Data are represented as mean ± SD, with N = 10 per group.

    Article Snippet: Omecamtiv Mecarbil (Adooq Bioscience, #A11206) and Mavacamten (MedChemExpress, #HY-109037) were initially dissolved in DMSO at a concentration of 10 mM.

    Techniques: